358 related articles for article (PubMed ID: 1380258)
1. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
Matsushita S; Maeda H; Kimachi K; Eda Y; Maeda Y; Murakami T; Tokiyoshi S; Takatsuki K
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1107-15. PubMed ID: 1380258
[TBL] [Abstract][Full Text] [Related]
2. Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120.
Wang HW; Cole D; Jiang WZ; Jin HT; Fu N; Chen ZL; Jin NY
Clin Exp Immunol; 2005 Jul; 141(1):72-80. PubMed ID: 15958072
[TBL] [Abstract][Full Text] [Related]
3. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
[TBL] [Abstract][Full Text] [Related]
4. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.
Posner MR; Elboim HS; Cannon T; Cavacini L; Hideshima T
AIDS Res Hum Retroviruses; 1992 May; 8(5):553-8. PubMed ID: 1381201
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
[TBL] [Abstract][Full Text] [Related]
6. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
[TBL] [Abstract][Full Text] [Related]
8. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.
Cavacini LA; Emes CL; Wisnewski AV; Power J; Lewis G; Montefiori D; Posner MR
AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1271-80. PubMed ID: 9764911
[TBL] [Abstract][Full Text] [Related]
9. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
10. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
Front Immunol; 2018; 9():3163. PubMed ID: 30697215
[TBL] [Abstract][Full Text] [Related]
11. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits.
Fung MS; Sun CR; Liou RS; Gordon W; Chang NT; Chang TW; Sun NC
J Immunol; 1990 Oct; 145(7):2199-206. PubMed ID: 2398276
[TBL] [Abstract][Full Text] [Related]
13. Variable region gene utilization and mutation in a group of neutralizing murine anti-human immunodeficiency virus type 1 principal neutralizing determinant antibodies.
Pirofski LA; Thomas EK; Scharff MD
AIDS Res Hum Retroviruses; 1993 Jan; 9(1):41-9. PubMed ID: 7678971
[TBL] [Abstract][Full Text] [Related]
14. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
[TBL] [Abstract][Full Text] [Related]
15. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
[TBL] [Abstract][Full Text] [Related]
16. Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization.
Dickey C; Ziegner U; Agadjanyan MG; Srikantan V; Refaeli Y; Prabhu A; Sato A; Williams WV; Weiner DB; Ugen KE
DNA Cell Biol; 2000 Apr; 19(4):243-52. PubMed ID: 10798448
[TBL] [Abstract][Full Text] [Related]
17. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
[TBL] [Abstract][Full Text] [Related]
18. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
McKeating JA; Zhang YJ; Arnold C; Frederiksson R; Fenyö EM; Balfe P
Virology; 1996 Jun; 220(2):450-60. PubMed ID: 8661395
[TBL] [Abstract][Full Text] [Related]
19. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
20. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]